Citi initiated coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and an $86.00 price target, representing significant upside from the current price of $46.17. The firm's analysts highlighted ...
Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...
His effort paid off: Tim Andrews, 66, is only the second person known to be living with a pig kidney. Andrews is free from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback